How liver transporters are affected by obesity and metabolic diseases
Official title: Post-translational regulation of hepatic uptake transporters in health and disease
Funded at University of Kansas Medical Center · NIH-11130923 · Data updated 2026-11-12
This study is looking at how obesity and nonalcoholic fatty liver disease affect the liver's ability to process medications, focusing on how certain fats and cholesterol play a role, so we can better understand how these conditions might change how patients respond to drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | July 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $378,081 |
| NIH project number | 5R01GM149665-02 |
| Project ID | NIH-11130923 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with obesity, metabolic syndrome, or nonalcoholic fatty liver disease.
✕Less likely to help
Patients without metabolic disorders or liver diseases may not benefit from this research.
What this research studies
This research investigates how conditions like obesity and nonalcoholic fatty liver disease (NAFLD) impact liver transporters that are crucial for drug metabolism and liver function. The study focuses on understanding the role of free cholesterol and lipid composition in regulating these transporters, specifically NTCP, OATP1B1, and OCT1. By examining these mechanisms, the research aims to provide insights into how these changes can affect drug responses and safety profiles for patients. The approach includes analyzing liver cells to determine how their function is altered in the presence of metabolic disorders.
Why it matters
Potential benefit: If successful, this research could lead to improved drug therapies and safety for patients with metabolic syndrome and liver diseases.
How similar studies have gone: Previous research has shown promising results in understanding liver transporter regulation, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of Kansas Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Hagenbuch, Bruno — University of Kansas Medical Center
- Study coordinator: Hagenbuch, Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.